# EDGAR Filing Document

**Accession Number:** 0001981662
**File Stem:** 0001213900-26-069883
**Filing Date:** 2026-6
**Character Count:** 39833
**Document Hash:** 9edf0827ad86657049160d45dab2749e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-069883.hdr.sgml**: 20260618

**ACCESSION NUMBER**: 0001213900-26-069883

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260618

**FILED AS OF DATE**: 20260618

**DATE AS OF CHANGE**: 20260618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NewGenIvf Group Ltd
- **CENTRAL INDEX KEY:** 0001981662
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42004
- **FILM NUMBER:** 261100508

**BUSINESS ADDRESS:**
- **STREET 1:** 13/F, PS TOWER, SUKHUMVIT 21 RD (ASOKE)
- **CITY:** BANGKOK
- **STATE:** W1
- **ZIP:** 0000
- **BUSINESS PHONE:** 852-2861-1666

**MAIL ADDRESS:**
- **STREET 1:** 1/F, PIER 2, CENTRAL
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 999077

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASPAC I Mini Acquisition Corp.
- **DATE OF NAME CHANGE:** 20230614

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **June 2026**

Commission File Number: 001-42004

**NEWGENIVF GROUP LIMITED**

**36/39-36/40, 13th Floor, PS Tower**

**Sukhumvit 21 Road (Asoke)**

**Khlong Toei Nuea Sub-district**

**Watthana District, Bangkok 10110**

**Thailand**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**EXPLANATORY NOTE**

On June 18, 2026, NewGenIvf Group Limited (the "Company") announced that it had entered into an additional share purchase agreement ("Additional SPA") with PredicXion Group Limited ("PredicXion" or "K25.ai"), to acquire an additional 4% equity in PredicXion (the "Acquisition"). Upon completion of the Acquisition, the Company's aggregate ownership interest in K25.ai shall increase to 10%. A copy of the press release issued by the Company on June 18, 2026 is furnished as Exhibit 99.1 and the Additional SPA is filed as Exhibit 10.1. The descriptions below are qualified in their entirety by reference to the full text of those exhibits.

**Additional Share Purchase Agreement**

Under the Additional SPA, the Company will acquire an additional 4% equity interest in PredicXion Group Limited for aggregate consideration of US$4,000,000, consisting of (i) US$1,900,000 payable in cash or digital assets and (ii) 1,500,000 newly issued Class A ordinary shares of the Company. Upon signing of the Additional SPA, the Company will pay a cash deposit of US$100,000, and shall pay the balance of US$1,900,000 on or before 30 September 2026. Upon completion of this transaction together with the Company's prior acquisition under the Original SPA, the Company will hold an aggregate 10% equity interest in PredicXion Group Limited based on an implied valuation of US$100,000,000. The closing of the transactions contemplated by the Additional SPA is subject to the satisfaction of customary closing conditions.

**Exemption from Registration**

The Class A ordinary shares of the Company to be issued as part of the consideration under the Additional SPA will be issued in reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), provided by Section 4(a)(2) of the Securities Act and/or Regulation S promulgated thereunder, as a transaction by an issuer not involving any public offering. The Class A ordinary shares so issued will be "restricted securities" within the meaning of Rule 144 under the Securities Act.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 10.1 | [Share Purchase Agreement between NewGenIvf Group Limited and PredicXion Group Limited dated June 18, 2026](ea029516101ex10-1.htm) |
| 99.1 | [Press release](ea029516101ex99-1.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 18, 2026

---

| | |
|:---|:---|
| **NewGenIvf Group Limited** | **NewGenIvf Group Limited** |
| By: | /s/ Wing Fung Alfred Siu |
| Name: | Wing Fung Alfred Siu |
| Title: | Chairman of the Board and Director |

---

## Exhibit 10.1

**Exhibit 10.1**

**SHARE PURCHASE AGREEMENT**

**For a Further Additional 4% of PredicXion Group Limited**

Date: 18 June 2026

**Parties**

This Share Purchase Agreement (the "Agreement") is made by and among:

1. PredicXion Group Limited, a company organised under the laws of the British Virgin Islands, with registered address at Aegis Chambers, 1st floor, Ellen Skelton Building, 3076 Sir Francis Drake's Highway, Road Town, Tortola, VG1110, British Virgin Islands (the "Company");

2. NewGenIVF Group Limited, a British Virgin Islands incorporated company, with registered address at 1/F, Pier 2, Central, Hong Kong (the "Buyer"); and

3. The shareholders of the Company listed in Schedule A (each a "Seller" and collectively, the "Sellers"). Each of the Company, Buyer and the Sellers is referred to as a "Party" and collectively as the "Parties".

**Recitals**

(A) The Buyer has previously agreed to acquire an initial equity interest in the Company, including an additional 4% equity interest under the Original SPA.

(B) As of the date of this Agreement, US$1,700,000 remains outstanding under the Original SPA. Buyer agrees to pay US$700,000 on or before 18 June 2026, leaving US$1,000,000 payable on or before 31 August 2026.

(C) Buyer wishes to acquire, and the Sellers wish to sell, a further additional 4% equity interest in the Company on the terms set out in this Agreement. Upon completion of the Original SPA and this Agreement, Buyer shall hold an aggregate 10% equity interest in the Company based on an implied Company valuation of US$100,000,000.

(D) This Agreement is intended to be the sole binding agreement governing the sale and purchase of the Further Additional Shares. Any prior heads of agreement, term sheet, memorandum, understanding, discussion, email, draft or other arrangement relating to the Further Additional Shares is superseded in full and has no continuing legal effect, except for accrued payment, issuance or delivery obligations expressly restated in this Agreement.

**1. Definitions and Interpretation**

**"Additional Original SPA Payment"** means US$700,000 payable by Buyer on or before 18 June 2026 toward the outstanding balance under the Original SPA.

"Balance Cash Payment" means US$1,900,000 in immediately available funds, payable in cash, stablecoin or other cryptocurrency acceptable to the Sellers, to the Sellers on or before the Initial Deadline.

**"Business Day"** means a day other than a Saturday, Sunday or public holiday on which banks are open for general business in the British Virgin Islands, Singapore and Hong Kong.

**"Buyer Default Event" means Buyer fails to deliver either (i) the First Outstanding Balance by 31 August 2026 or (ii) the Balance Cash Payment by the Initial Deadline, after the applicable Buyer closing conditions in Clause 5.2 have been satisfied or waived, other than conditions that by their nature are to be satisfied at Closing, and provided that neither the Company nor the Sellers are then in material breach of their Closing delivery obligations.**

**"Closing"** means completion of the sale and purchase of the Further Additional Shares in accordance with Clause 4.

**"Closing Date"** means the date on which Closing occurs, which shall be within two Business Days after the Sellers receive the Balance Cash Payment, unless the Sellers agree otherwise in writing.

**"Consideration Shares"** means 1,500,000 Class A ordinary shares of Buyer issued or to be issued to the Sellers or their nominees under this Agreement, having an agreed transaction value of US$2,000,000.

**"First Outstanding Balance"** means US$1,000,000 remaining payable under the Original SPA after receipt of the Additional Original SPA Payment, payable on or before 31 August 2026.

**"Further Additional Shares"** means an aggregate of 4% of the fully diluted equity of the Company, allocated among the Sellers as set out in Schedule A.

"Immediate Cash Deposit" means US$100,000 in cash, stablecoin or other cryptocurrency paid or to be paid by Buyer to the Sellers under this Agreement.

**"Initial Deadline"** means 30 September 2026.

**"Minimum Price"** means the lower of (i) the Nasdaq official closing price on the trading day immediately preceding the relevant reference date, and (ii) the average Nasdaq official closing price for the five trading days immediately preceding such reference date.

**"Original SPA"** means the prior share purchase agreement(s) between the relevant parties in respect of Buyer's existing investment in the Company, including the additional 4% equity interest for which US$1,700,000 remains outstanding as of the date of this Agreement.

**"Seller Dedicated Wallet"** means the digital asset wallet address, or wallet addresses, designated in writing by the Sellers for receipt of the cash, stablecoin or digital asset portion of the Balance Cash Payment.

In this Agreement, references to clauses and schedules are to clauses and schedules of this Agreement. Headings are for convenience only and do not affect interpretation. The word "including" means "including without limitation".

**2. Sale and Purchase**

2.1 Each Seller sells, and Buyer purchases, the number of Further Additional Shares set opposite its name in Schedule A, free and clear of all liens, claims and encumbrances, subject to and in accordance with this Agreement.

2.2 Buyer acknowledges that the Further Additional Shares represent a further additional 4% equity interest in the Company only. No other equity, warrant, option, board nomination right, agency right, exclusivity right, revenue participation right, veto right, information right, anti-dilution right, redemption right or other special right is granted except as expressly stated in this Agreement or the Original SPA.

2.3 Time is of the essence for Buyer's payment obligations under this Agreement and the Original SPA.

2.4 The Sellers are not required to transfer or register the Further Additional Shares until the Balance Cash Payment and the First Outstanding Balance have been received in full, unless otherwise agreed by the Sellers in writing.

**3. Consideration**

3.1 The total consideration for the Further Additional Shares is US$4,000,000, payable as follows:

---

| | | |
|:---|:---|:---|
| **Component** | **Amount** | **Status / Timing** |
| Immediate Cash Deposit | US$100,000 | Non-refundable once received, except in the case of Seller Default under Clause 8.2. |
| Consideration Shares | 1,500,000 Class A ordinary shares of Buyer, agreed transaction value US$2,000,000 | Issued or to be issued to the Sellers or their nominees as part of the consideration. |
| Balance Cash Payment | US$1,900,000 | Payable on or before the Initial Deadline. |

---

3.2 Buyer shall separately pay the Additional Original SPA Payment on or before 18 June 2026. Such payment shall reduce the outstanding balance under the Original SPA to US$1,000,000, payable on or before 31 August 2026. The Additional Original SPA Payment shall not be credited against the consideration payable under this Agreement.

3.3 Buyer confirms that the Consideration Shares have been validly issued, or will be validly issued, at a price of US$1.3333 per share, which Buyer represents is not lower than the applicable Minimum Price and does not require shareholder approval under applicable Nasdaq rules.

3.4 All payments shall be made free and clear of, and without deduction or withholding for, any bank charges, gas fees, taxes, set-off, counterclaim or other deductions, unless required by law. Any such required deduction shall be grossed up by Buyer so that the Sellers receive the full amount that would have been received absent such deduction.

3.5 The Immediate Cash Deposit and Consideration Shares are not financing or diligence deposits and shall not be refundable merely because Buyer changes its investment decision, fails to obtain internal or external financing, experiences a decline in share price or market value, or wishes to renegotiate the terms of this Agreement.

**4. Closing**

4.1 Closing shall take place remotely by exchange of documents, signatures and payment confirmations on the Closing Date.

4.2 Deliveries by Sellers and Company. At or prior to Closing, the Sellers and the Company shall deliver, or procure delivery of:

● Duly executed transfer forms and share certificates, or equivalent evidence of title, for the Further Additional Shares;

● Certified copies of resolutions of the Company's board and, if applicable, shareholders approving the transaction;

● An updated register of members or equivalent evidence reflecting Buyer as holder of the Further Additional Shares, subject to receipt of the Balance Cash Payment and First Outstanding Balance;

● A certificate of the Company confirming that the Closing Conditions have been satisfied or waived.

4.3 Deliveries by Buyer. At or prior to Closing, Buyer shall deliver:

● The Balance Cash Payment by verified on-chain transfer to the Seller Dedicated Wallet, or by such other payment method as the Sellers may expressly agree in writing;

● Evidence reasonably satisfactory to the Sellers that the Consideration Shares have been validly issued, fully paid, non-assessable and recorded in the relevant register or transfer agent records in the name of the Sellers or their nominees;

● Certified copies of Buyer board approvals and any other corporate approvals required for the transaction and the issuance of the Consideration Shares;

● Evidence that the First Outstanding Balance has been paid in full, unless waived by the Sellers in writing.

4.4 The Sellers are not required to transfer or register the Further Additional Shares until the Balance Cash Payment and First Outstanding Balance have been received in full in cleared or confirmed on-chain funds.

**5. Closing Conditions**

5.1 The obligations of the Sellers and the Company to complete Closing are subject to satisfaction or written waiver by the Sellers of the following conditions:

● Buyer has delivered the Immediate Cash Deposit, the Consideration Shares and the Balance Cash Payment in accordance with this Agreement;

● Buyer has paid the Additional Original SPA Payment and the First Outstanding Balance in accordance with this Agreement and the Original SPA, unless waived by the Sellers in writing;

● Buyer's representations and warranties are true and not misleading in all material respects at signing and Closing;

● Buyer has obtained all corporate, regulatory, Nasdaq, SEC and third-party approvals required for entry into, performance of and payment under this Agreement, including issuance of the Consideration Shares, if any;

● No trading suspension, delisting determination, shareholder approval requirement, injunction, regulatory restriction or other event exists that would materially impair the value, validity, issuance, receipt, ownership or transferability of the Consideration Shares.

5.2 The obligations of Buyer to complete Closing are limited to the following conditions, each of which shall be interpreted narrowly:

● The Sellers have authority and title to transfer the Further Additional Shares;

● The Company has obtained necessary corporate approvals to recognise the transfer of the Further Additional Shares;

● All pre-emptive rights of existing shareholders of the Company with respect to the Further Additional Shares have been waived or are not applicable;

● There is no court order or specific regulatory prohibition that legally prevents the transfer of the Further Additional Shares.

5.3 Buyer's confirmatory due diligence is limited to corporate authority, capitalisation, ownership of the Further Additional Shares and material legal restrictions that would prevent Closing. Buyer shall be deemed to have completed and satisfied its due diligence condition unless it delivers a written notice specifying in reasonable detail any material uncured legal impediment within five Business Days after receipt of the Company's due diligence materials. Buyer may not refuse to close on the basis of valuation, market conditions, business plan, product roadmap, regulatory developments generally affecting the industry, or matters disclosed to Buyer before signing.

5.4 Buyer confirms that its obligation to pay the Balance Cash Payment is not subject to financing, fundraising, share price, market capitalisation, board composition, public announcement, third-party investor consent, analyst coverage, investor relations outcome, or any condition not expressly set out in this Agreement.

**6. Representations and Warranties**

**6.1 By each Seller**

Each Seller severally, and not jointly, represents and warrants solely with respect to itself and the shares sold by it that:

● such Seller has good and marketable title to its portion of the Further Additional Shares, free of all liens;

● such Seller has full power and authority to enter into this Agreement and to transfer its portion of the Further Additional Shares;

● no consent or approval is required for such transfer, except as disclosed to Buyer in writing or obtained before Closing;

● if such Seller receives any Consideration Shares, such Seller is a sophisticated investor for the purpose of US securities laws and is not acquiring the Consideration Shares on behalf of, or for the account or benefit of, any US person as defined in Regulation S under the Securities Act.

**6.2 By the Company**

The Company represents and warrants that:

● it is duly organised and validly existing under BVI law;

● its authorised and outstanding share capital is as set out in Schedule B;

● to the Company's knowledge, except as disclosed to Buyer in writing, there are no pending litigation proceedings or material regulatory orders specifically against the Company that would legally prevent Closing;

● if the Company receives any Consideration Shares, the Company is a sophisticated investor for the purpose of US securities laws and is not acquiring the Consideration Shares on behalf of, or for the account or benefit of, any US person as defined in Regulation S under the Securities Act.

**6.3 By Buyer**

Buyer represents and warrants that:

● it is duly organised and validly existing under BVI law and has full power and authority to enter into and perform this Agreement;

● it is a Foreign Private Issuer listed on Nasdaq under the symbol "NIVF";

● the execution and performance of this Agreement and the issuance of the Consideration Shares have been duly authorised and do not require further shareholder approval;

● Buyer's SEC filings are current in all material respects and Buyer is in compliance with applicable Nasdaq listing standards, except as expressly disclosed in writing to the Company before signing;

● Buyer has sufficient cash, cash equivalents or committed funding to pay the Balance Cash Payment and First Outstanding Balance when due and acknowledges that lack of financing is not a defence to non-payment;

● Buyer has not relied on any representation, warranty, projection, forecast, valuation, business plan, public-market pathway, listing expectation, token, licensing outcome, regulatory outcome, product launch timing, user metric, celebrity or entertainment collaboration, or other statement not expressly set out in this Agreement;

● Buyer acknowledges that the default payment, non-refundable consideration and remedies in Clause 8 are commercially reasonable, negotiated between sophisticated parties, and reflect the risk allocation agreed under this Agreement.

**7. Covenants**

7.1 Buyer shall cooperate promptly and in good faith to complete Closing and shall not take any action intended to delay, frustrate, unwind or impair the transactions contemplated by this Agreement.

7.2 The Initial Deadline may be extended only by mutual written consent of Buyer and the Sellers or the Company. Any extension must be evidenced by a written instrument signed by Buyer and the Sellers or the Company. If extended, Buyer shall pay the Balance Cash Payment on or before the extended deadline.

7.3 To the extent any portion of the consideration is separately contributed, advanced or assigned to the Company, such funds shall be used by the Company as working capital for expansion of the K25.ai platform in the Asia-Pacific region, subject to the Company's board-approved budget and business plan.

7.4 Buyer shall not make any public announcement, press release, filing or disclosure regarding this Agreement, the Company, K25.ai or the Sellers without the Company's prior written consent, except to the extent required by applicable law or Nasdaq or SEC rules. Where disclosure is required, Buyer shall consult with the Company in advance and use reasonable efforts to limit the disclosure to the minimum legally required content.

7.5 The Parties shall keep this Agreement and all non-public information received in connection with it confidential, except as required by law, regulation, court order, Nasdaq or SEC rules, or to professional advisers who are bound by confidentiality obligations.

7.6 Buyer shall not assign, transfer or delegate any right or obligation under this Agreement without the prior written consent of the Company and the Sellers. Any purported assignment without such consent shall be void.

7.7 Each Party shall execute and deliver such further documents and take such further actions as may be reasonably required to give effect to this Agreement.

**8. Default and Remedies**

**8.1 Buyer Default and 100% Default Payment**

If Buyer fails to deliver either (i) the First Outstanding Balance to the Sellers by 31 August 2026 or (ii) the Balance Cash Payment to the Sellers by the Initial Deadline, and the applicable Buyer closing conditions in Clause 5.2 have been satisfied or waived other than conditions that by their nature are to be satisfied at Closing, such failure shall constitute a Buyer Default Event.

Upon the occurrence of a Buyer Default Event:

● Buyer shall be deemed to have forfeited the transaction and shall have no right to receive any Further Additional Shares;

● the Immediate Cash Deposit shall be forfeited to the Sellers and shall be non-refundable;

● the Consideration Shares shall remain the property of the Sellers or their nominees and Buyer shall not seek cancellation, rescission, reversal, clawback, transfer restriction, injunction or similar relief in respect of such shares;

● Buyer shall, within three Business Days after written demand by the Sellers, pay to the Sellers an additional amount equal to 100% of the missed payment amount as agreed liquidated damages for Buyer's failure to complete, being (i) US$1,000,000 if Buyer fails to pay the First Outstanding Balance by 31 August 2026, and/or (ii) US$1,900,000 if Buyer fails to pay the Balance Cash Payment by the Initial Deadline;

● the Parties acknowledge that the 100% default payment, together with the Sellers' right to retain the Immediate Cash Deposit and Consideration Shares to the maximum extent enforceable by law, is a genuine pre-estimate of loss and a commercially reasonable allocation of risk between sophisticated parties, having regard to lost transaction certainty, lost opportunity cost, market risk, reputational risk, legal and advisory costs, and strategic delay, and is not intended to operate as a penalty;

● if retention of any Consideration Shares is restricted, cancelled, voided or otherwise not legally effective for any reason caused by Buyer, Buyer shall pay the Sellers the agreed transaction value of such affected shares in cash as a debt due and payable on demand, without prejudice to the 100% default payment;

● the Sellers may pursue debt recovery, specific performance of payment obligations, injunctive relief and any other remedies available at law or in equity, without any obligation to mitigate by seeking another buyer for the Further Additional Shares.

**8.2 Seller Default**

If the Sellers receive all consideration and amounts payable under this Agreement and the Original SPA in full, including the Immediate Cash Deposit, the Consideration Shares, the Balance Cash Payment, the Additional Original SPA Payment and the First Outstanding Balance, and the Buyer has otherwise complied in all material respects with this Agreement, and the Sellers then fail to transfer the Further Additional Shares within 10 Business Days after receipt of all such amounts and required Buyer deliverables, Buyer shall be entitled to specific performance. No delay or failure caused by Buyer, Buyer's transfer agent, registrar, custodian, regulatory restriction, incomplete Buyer deliverables, or any matter outside the Sellers' reasonable control shall constitute Seller Default. If specific performance is finally determined to be unavailable due solely to Seller default, Buyer may terminate this Agreement and receive return of the Balance Cash Payment and, to the extent actually received and retained by the Sellers, the Immediate Cash Deposit and Consideration Shares or their cash-equivalent value. Buyer shall not be entitled to consequential, indirect, punitive, special or loss-of-profit damages.

**8.3 Remedies Cumulative**

Except as expressly provided otherwise, the rights and remedies in this Agreement are cumulative and not exclusive.

**9. Termination**

9.1 This Agreement may be terminated:

● by mutual written consent of Buyer and the Company or the Sellers;

● by the Sellers if a Buyer Default Event occurs;

● by Buyer only if the Sellers fail to transfer the Further Additional Shares within 10 Business Days after receipt in full of the Balance Cash Payment and First Outstanding Balance and Buyer is not in breach of this Agreement;

● automatically upon Closing.

9.2 Termination shall not affect accrued rights, payment obligations, liquidated damages, confidentiality obligations, dispute resolution, costs, fraud, wilful misconduct, indemnities, remedies, or any provision intended to survive termination.

**10. Governing Law and Dispute Resolution**

10.1 This Agreement and any non-contractual obligations arising out of or in connection with it shall be governed by the laws of the British Virgin Islands.

10.2 Any dispute arising out of or relating to this Agreement shall be finally resolved by arbitration administered by the BVI International Arbitration Centre under the BVI Arbitration Rules. The number of arbitrators shall be one. The seat of arbitration shall be the British Virgin Islands. The language of the arbitration shall be English.

10.3 Nothing in this Clause prevents any Party from seeking urgent interim or injunctive relief from any court of competent jurisdiction.

**11. Notices**

Any notice under this Agreement shall be in writing and delivered by email, courier or personal delivery to the addresses or email addresses notified by the relevant Party in writing. Notices by email shall be deemed received when sent, provided that no bounce-back or delivery failure notice is received. Each Party shall promptly notify the others of any change to its notice details.

**12. Miscellaneous**

12.1 Entire Agreement. This Agreement constitutes the entire agreement between the Parties in relation to the sale and purchase of the Further Additional Shares and supersedes all prior agreements, heads of agreement, term sheets, drafts, discussions, understandings, emails and arrangements relating to the Further Additional Shares. No prior document or communication shall have any legal effect except to the extent expressly restated in this Agreement.

12.2 Amendments. Any amendment, waiver or consent must be in writing and signed by the Party against whom enforcement is sought.

12.3 Counterparts and Electronic Signatures. This Agreement may be executed in counterparts and by electronic signature, each of which shall be deemed an original and all of which together constitute one instrument.

12.4 Severability. If any provision is held to be invalid or unenforceable, the remaining provisions shall remain in full force, and the invalid or unenforceable provision shall be replaced by a valid and enforceable provision that most closely reflects the Parties' original commercial intent.

12.5 Costs. Each Party shall bear its own costs unless otherwise provided in this Agreement, except that the prevailing Party in any enforcement action shall be entitled to recover reasonable legal fees, arbitration costs and enforcement costs.

12.6 Taxes. Buyer shall be responsible for any stamp duty, transfer tax, issuance tax, withholding tax or similar tax arising from its purchase of the Further Additional Shares or issuance of the Consideration Shares, other than taxes imposed on the Sellers' net income.

12.7 No Partnership. Nothing in this Agreement creates a partnership, joint venture, fiduciary relationship or agency between the Parties.

12.8 Third Party Rights. A person who is not a Party has no right to enforce any term of this Agreement, except that a Seller nominee receiving Consideration Shares may enforce provisions relating to those shares.

**Execution**

IN WITNESS WHEREOF, the Parties have executed this Share Purchase Agreement as of the date first written above.

---

| | |
|:---|:---|
| PredicXion Group Limited | PredicXion Group Limited |
| By: | /s/ Kong Yiu CHEUNG |
| Name: | Kong Yiu CHEUNG |
| Title: | CEO |

---

---

| | |
|:---|:---|
| NewGenIVF Group Limited | NewGenIVF Group Limited |
| By: | /s/ Alfred Siu |
| Name: | Alfred Siu |
| Title: | CEO |

---

---

| | |
|:---|:---|
| Sellers (as per Schedule A) | Sellers (as per Schedule A) |
| By: | /s/ Kong Yiu CHEUNG |
| Name: | Kong Yiu CHEUNG |
| Title: | CEO |

---

**Schedule A - Sellers and Allocation of Further Additional Shares (4%)**

---

| | |
|:---|:---|
| **Seller Name** | **Shares Sold under this Agreement** |
| Kong Yiu CHEUNG (Andy Cheung) | 100% of the 4% Further Additional Shares |

---

**Schedule B - Capitalisation of the Company**

Upon completion of all obligated payments under the Original SPA and this Agreement, and upon successful Closing, Buyer shall hold an aggregate 10% equity interest in the Company. The Company's cap table and register of members shall be fully updated concurrently with Closing to reflect the transactions completed as of Closing.

**Schedule C - Payment Summary**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Payment** | **Amount** | **Amount** | **Deadline** | **Treatment** |
| Additional Original SPA Payment | US$ | 700000 | 18 June 2026 | Toward Original SPA outstanding balance. |
| First Outstanding Balance | US$ | 1000000 | 31 August 2026 | Remaining balance under Original SPA. |
| Immediate Cash Deposit | US$ | 100000 | 18 June 2026 | Deposit for Further Additional Shares; non-refundable except Seller Default. |
| Balance Cash Payment | US$ | 1900000 | 30 September 2026 | Balance for Further Additional Shares. |

---

## Exhibit 99.1

**Exhibit 99.1**

**NewGen Increases K25.ai Ownership to 10% in Closed Pre-A Round at US$100 Million Valuation with Total US$10 Million Invested**

K25.ai to complete its US$10 million Pre-A at a US$100 million valuation and is now raising its Series A to accelerate product launch and regional expansion

NewGen's expanded stake and exclusive Asia-Pacific agency rights deepen its strategic participation in K25.ai's next phase of growth

BANGKOK, June 18, 2026 – NewGenIVF Group Limited (Nasdaq: NIVF) ("NewGen" or the "Company"), a technology-driven, diversified growth company, today announced that it has executed an agreement for a further US$4 million strategic investment in K25.ai. The transaction completes K25.ai's US$10 million Pre-A round at a US$100 million valuation and, upon completion and satisfaction of the applicable closing conditions, is expected to increase NewGen's aggregate ownership interest in K25.ai to 10%. With the Pre-A round now closed, K25.ai has commenced its Series A fundraising.

The investment follows NewGen's initial US$2 million investment announced in May 2026 and its subsequent US$4 million investment announced on June 4, 2026. The completed US$10 million Pre-A provides K25.ai with strategic backing as it moves toward product launch, while the newly launched Series A is intended to support commercialization, applicable regulatory licensing and expansion across selected Asian markets.

K25.ai is an AI-native livestreaming and watch-to-predict information market platform purpose-built for Asia-Pacific. Positioned as "Twitch × Polymarket × ChatGPT," K25.ai is developing a new category of interactive information markets that combines creator-led livestreaming, AI-assisted market creation and resolution, and real-time community participation.

NewGen believes the expanded investment provides early strategic exposure to a differentiated platform operating at the convergence of artificial intelligence, livestreaming and prediction-market infrastructure. The transaction reflects NewGen's conviction in the long-term potential of AI-powered information markets and K25.ai's ability to build a category-defining platform for Asia-Pacific, subject to execution, market conditions and applicable regulatory requirements.

Beyond its equity ownership, NewGen holds exclusive Asia-Pacific agency rights with K25.ai, creating an additional commercial pathway to support regional partnerships and distribution across permitted markets. Together, the expected 10% ownership position and agency relationship would provide NewGen with meaningful economic participation and strong strategic alignment with K25.ai's regional growth.

Alfred Siu, Founder, Chairman and Chief Executive Officer of NewGen, commented, "Entering into this additional agreement to complete our aggregate US$10 million commitment to K25.ai and securing an expected 10% ownership position at the same US$100 million Pre-A valuation represents a compelling strategic milestone for NewGen. We believe K25.ai is building a highly differentiated platform at the intersection of AI, livestreaming and information markets. Together with our exclusive Asia-Pacific agency rights, this expanded investment positions NewGen to participate meaningfully in K25.ai's product launch, commercialization and next phase of regional growth."

Andy Cheung, Founder and Chief Executive Officer of K25.ai, commented, "The successful close of our US$10 million Pre-A at a US$100 million valuation marks a defining milestone for K25.ai and provides strong strategic validation for our vision of building Asia-Pacific's next-generation AI-powered information market. With NewGen's backing, our Pre-A is now complete and we have officially commenced our Series A fundraising. This next round is designed to accelerate product launch, advance applicable regulatory licensing in selected Asian markets, deepen our creator and strategic partner ecosystem, and position K25.ai for its next phase of regional growth."

Further details regarding the Agreement and the proposed transaction will be included in a Form 6-K to be furnished to the U.S. Securities and Exchange Commission.

**About K25.ai**

K25.ai is an AI-native information market platform combining livestreaming, AI-assisted market creation and resolution, and interactive watch-to-predict experiences. Purpose-built for Asia-Pacific and positioned as "Twitch × Polymarket × ChatGPT," K25.ai is developing a creator-led platform for sports, esports, entertainment and other permitted event categories. The platform is progressing toward product launch and pursuing applicable regulatory licensing in selected markets. K25.ai does not offer services in jurisdictions where such activities are restricted or prohibited. To learn more, visit www.k25.ai.

**About NewGenIVF Group Limited**

NewGenIVF Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF's legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company's website is not incorporated by reference into this press release.

**Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "outlook," "would," "may," "potential," "aim," "seek," "project," "positions," "conviction," "intends," "designed to," and similar expressions, or their negatives, although not all forward-looking statements contain these identifying words. These statements include, among others, statements regarding the proposed investment in K25.ai, the expected completion of the transaction, NewGen's anticipated ownership interest, K25.ai's planned product launch, future financing initiatives, regulatory licensing efforts, regional expansion and growth prospects, and the expected strategic and commercial benefits of the relationship between NewGen and K25.ai. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including the risk that the transaction may not be completed on the anticipated terms or at all; the risk that closing conditions may not be satisfied, including the Company's ability to fund its remaining payment obligations under the agreement; market, regulatory and financing conditions; K25.ai's ability to develop and launch its platform, obtain applicable licenses and execute its growth strategy; and other risks described in NewGen's filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. NewGen undertakes no obligation to update any forward-looking statement, except as required by law. This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities of NewGenIVF Group Limited, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

**Contacts**

**NewGen Investor Relations Contact**<br> ICR, LLC<br> Robin Yang<br> Phone: +1 (212) 537-3847<br> Email: NewgenivfIR@icrinc.com

**K25.ai Media Contact**<br> Email: media@k25.ai

**K25.ai Investor Relations Contact**<br> Email: ir@k25.ai